FEATURE: Cancer Therapeutics CRC (CTx) - A new portfolio of drug discovery opportunities

2012-05-31 09:37:04

CTx, our Australian Partner consortium is one of the largest public/private partnerships in cancer drug discovery in the world.

Founded in January 2007 to benefit Australian researchers and their research institutes, CTx is supported under the Australian Government’s Cooperative Research Centres Programme.

A dedicated cancer drug discovery company underpinned by AUD148M in public/private partnership funds, CTx works closely with leading Australian researchers and institutes to discover, protect and develop small molecule discoveries into pre-clinical drug candidates with commercial potential.

CTx is focused on developing a pipeline of high quality leads and preclinical small molecule drug candidates that target specific pathways related to the tumour microenvironment or growth. All programmes are led by Dr Ian Street – CTx's Chief Scientific Officer.

CTx has recently appointed a new CEO – Dr Warwick Tong – who brings more than 19 years experience, including at GlaxoSmithKline and MedInnovate Ltd.

With the help of CRT, its global commercialisation partner, CTx is looking to establish drug discovery collaborations with pharmaceutical and biotechnology companies who are best placed to take projects forward from an early development stage.

CRT has selected a number of early stage small molecule programs, backed up with data-rich packages to add to its portfolio:

Inhibition of isoprenylcysteine carboxyl methytransferase (ICMT) blocks post translational activation of kRAS, a protein implicated in one third of human cancers.

CCL, MCL, Melanoma
Inhibition of protein arginine methyltransferase 5 (PRMT5) activates the tumour suppressor protein, p53.

Multiple Cancers
Inhibition will stop the E3 ubiquitin ligase E6AP targeting tumour suppressors for destruction.

Multiple Cancers
Inhibition of seven in absentia homolog (SIAH), a pro-tumourigenic E3 ubiquitin ligase, interferes with several critical aspects of cancer progression. 

For more information about CTx or any of the collaborative opportunities, please contact Tanya Moore (


Notes to editors